Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53.
Acetylation
Animals
Cell Transformation, Neoplastic
E1A-Associated p300 Protein
/ metabolism
Exosomes
/ immunology
Extracellular Vesicles
/ metabolism
HEK293 Cells
Humans
Melanoma
/ immunology
Membrane Proteins
/ metabolism
Mice
Mice, Inbred C57BL
Molecular Chaperones
/ metabolism
Monocytes
/ immunology
Nuclear Proteins
/ metabolism
Peptide Fragments
/ metabolism
Phosphoproteins
/ metabolism
Sialoglycoproteins
/ metabolism
Tumor Microenvironment
Tumor Suppressor Protein p53
/ metabolism
BAG6/CBP/p300-p53
exosomes
extracellular vesicles
melanoma
metastasis
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
05
2019
accepted:
15
07
2019
entrez:
20
9
2019
pubmed:
20
9
2019
medline:
29
9
2020
Statut:
epublish
Résumé
Extracellular vesicles released by tumor cells contribute to the reprogramming of the tumor microenvironment and interfere with hallmarks of cancer including metastasis. Notably, melanoma cell-derived EVs are able to establish a pre-metastatic niche in distant organs, or on the contrary, exert anti-tumor activity. However, molecular insights into how vesicles are selectively packaged with cargo defining their specific functions remain elusive.
Identifiants
pubmed: 31534536
doi: 10.7150/thno.36378
pii: thnov09p6047
pmc: PMC6735508
doi:
Substances chimiques
BAG6 protein, human
0
Bag6 protein, mouse
0
Membrane Proteins
0
Molecular Chaperones
0
Nuclear Proteins
0
Pag1 protein, mouse
0
Peptide Fragments
0
Phosphoproteins
0
Sialoglycoproteins
0
Trp53 protein, mouse
0
Tumor Suppressor Protein p53
0
bone sialoprotein (35-62), human
0
E1A-Associated p300 Protein
EC 2.3.1.48
EP300 protein, human
EC 2.3.1.48
Ep300 protein, mouse
EC 2.3.1.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6047-6062Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Int J Cancer. 2000 Aug 15;87(4):569-73
pubmed: 10918199
J Biol Chem. 2001 Sep 21;276(38):35500-11
pubmed: 11461913
J Gen Virol. 2002 Aug;83(Pt 8):2047-57
pubmed: 12124469
Mol Biol Evol. 2005 Aug;22(8):1661-72
pubmed: 15872155
Cancer Res. 2006 May 1;66(9):4795-801
pubmed: 16651434
J Proteome Res. 2006 Nov;5(11):3135-44
pubmed: 17081065
Genes Dev. 2007 Apr 1;21(7):848-61
pubmed: 17403783
Immunity. 2007 Dec;27(6):965-74
pubmed: 18055229
Nat Cell Biol. 2008 Jun;10(6):676-87
pubmed: 18454141
FEBS J. 2009 Apr;276(8):2201-12
pubmed: 19302216
J Biol Chem. 2009 Dec 4;284(49):34211-22
pubmed: 19801663
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Cancer Res. 2010 Feb 15;70(4):1281-5
pubmed: 20145139
J Clin Invest. 2010 Dec 1;120(12):4569-82
pubmed: 21041953
Curr Opin Cell Biol. 2011 Aug;23(4):452-7
pubmed: 21570275
Mol Cell. 2011 Jul 8;43(1):33-44
pubmed: 21726808
Immunobiology. 2012 Oct;217(10):982-5
pubmed: 22459270
Cancer Res. 2012 Jun 1;72(11):2746-56
pubmed: 22593198
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Mol Cancer Res. 2012 Jul;10(7):892-903
pubmed: 22648798
Int J Cancer. 2013 Feb 1;132(3):521-30
pubmed: 22733455
Nat Cell Biol. 2012 Jun 29;14(7):654-5
pubmed: 22743708
Cell Cycle. 2012 Jul 15;11(14):2717-28
pubmed: 22751435
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2110-6
pubmed: 22753494
Nat Med. 2012 Sep;18(9):1394-400
pubmed: 22863785
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Blood. 2013 May 2;121(18):3658-65
pubmed: 23509156
J Biol Chem. 2013 Nov 29;288(48):34295-303
pubmed: 24133212
Nat Rev Immunol. 2014 Mar;14(3):195-208
pubmed: 24566916
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4115-20
pubmed: 24591579
Tumour Biol. 2014 Oct;35(10):9855-8
pubmed: 24989925
Front Immunol. 2014 Aug 20;5:403
pubmed: 25191326
Cell. 2014 Oct 23;159(3):499-513
pubmed: 25417103
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394
Cell. 2015 May 21;161(5):1046-1057
pubmed: 26000481
Science. 2015 Nov 20;350(6263):985-90
pubmed: 26494174
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):16000-5
pubmed: 26668367
Cancer Res. 2016 Mar 15;76(6):1381-90
pubmed: 26719539
J Invest Dermatol. 2016 Feb;136(2):372-377
pubmed: 26802235
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
J Clin Invest. 2016 Apr 1;126(4):1139-43
pubmed: 27035805
Science. 2016 Apr 8;352(6282):145-6
pubmed: 27124439
Oncoimmunology. 2015 Aug 12;5(4):e1071008
pubmed: 27141373
Biochem Soc Trans. 2016 Jun 15;44(3):796-801
pubmed: 27284044
Sci Rep. 2016 Jun 17;6:28083
pubmed: 27312428
Oncogene. 2017 Feb 16;36(7):933-941
pubmed: 27477692
Eur J Cancer. 2016 Oct;66:34-46
pubmed: 27522248
Nat Cell Biol. 2016 Sep;18(9):1006-17
pubmed: 27548915
Sci Transl Med. 2016 Oct 19;8(361):361ra138
pubmed: 27798263
Oncoimmunology. 2016 Aug 19;5(10):e1219827
pubmed: 27853642
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Nat Rev Cancer. 2017 Jan;17(1):38-53
pubmed: 27932800
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Semin Cell Dev Biol. 2017 Jul;67:3-10
pubmed: 28077297
J Extracell Vesicles. 2017 Jul 3;6(1):1340746
pubmed: 28717426
Nat Commun. 2017 Jul 28;8(1):153
pubmed: 28751718
Semin Cell Dev Biol. 2018 Feb;74:66-77
pubmed: 28807885
Nat Commun. 2017 Nov 6;8(1):1319
pubmed: 29105655
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):
pubmed: 29158318
Cancer Res. 2017 Dec 1;77(23):6480-6488
pubmed: 29162616
Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4396-E4405
pubmed: 29686075
Cancers (Basel). 2018 Oct 05;10(10):null
pubmed: 30301144
EMBO Rep. 2019 Apr;20(4):null
pubmed: 30804014
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):455-468
pubmed: 31047959
Dev Cell. 2019 May 6;49(3):347-360
pubmed: 31063754